Table 1. Main characteristic of included studies.

Author	Year	Cancer types	Source of patients	Cases	Samples	Method	Cut-off value for positive	Follow-up (Months)
Li J5	2008	breast cancer	China	225	tissue	IHC	SI ≥ 4	80*
Hu GH14	2009	breast cancer	America	170	tissue	IHC	NR	180*
Su P15	2010	breast cancer	China	162	tissue	IHC	SI ≥ 4	/
Li C16	2011	breast cancer (triple-negative)	China	125	tissue	IHC	SI ≥ 4	70*
Tokunaga E23	2014	breast cancer	Japan	195	tissue	IHC	SI ≥ 4	119
Du C21	2014	breast cancer	China	118	tissue	IHC	SI ≥ 4	/
Tan LS25	2015	breast cancer (triple-negative)	China	112	tissue	IHC	SI ≥ 4	90
Meng F6	2011	epithelial ovarian cancer	China	81	tissue	IHC	SI ≥ 4	78
Li C17	2011	epithelial ovarian cancer	China	157	tissue	IHC	SI ≥ 4	/
Li C18	2012	ovarian cancer	China	101	tissue	IHC	SI ≥ 4	96
Li C22	2014	ovarian cancer	China	102	tissue	IHC	SI ≥ 3	>36
Dong R20	2014	ovarian cancer	China	76	tissue	IHC	SI ≥ 2	60
Zhou B26	2015	ovarian cancer	China	73	tissue	IHC	SI ≥ 4	80
Long M19	2013	cervical cancer	China	220	tissue	IHC	SI ≥ 3	/
Huang K7	2013	cervical cancer	China	90	tissue	IHC	positive rate ≥ 40%	80*
Song EL24	2014	cervical cancer	China	80	tissue	IHC	intensity ≥ 17.4%	60*
Song HT8	2010	endometrial cancer	China	174	tissue	IHC	SI ≥ 4	76
Wang Y27	2016	ovarian cancer	China	162	tissue	IHC	SI ≥ 3	78
Jin P28	2013	breast cancer	China	60	tissue	IHC	SI ≥ 2	125*

^*Extracted from survival curve; IHC: immunohistochemistry; SI: staining index = staining intensity × proportion of positive tumor.